TickerFacts.

Foxo Technologies Inc. (FOXO): Capital Expenditures

Annual figures by period end, from SEC filings.

$62.0K
Year ended 2025-12-31
$56.5K
Trailing 12 months to 2026-06-30
-17.4%
3-year compound annual growth
$118.0K2021-12-31: $118.0K2022-12-31: $110.0K2025-12-31: $62.0K$62.0K
2021-12-31 Capital Expenditures (USD) 2025-12-31
Period endedCapital ExpendituresChange YoYSource filing
2025-12-31$62.0Kn/a2026-04-15, From 2025-01-01
No annual figure between 2022-12-31 and 2025-12-31.
2022-12-31$110.0K-6.8%2024-06-06, From 2022-01-01
2021-12-31$118.0Kn/a2023-03-31, From 2021-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Services-Commercial Physical & Biological Research), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCapital ExpendituresChange YoY
Foxo Technologies Inc. (FOXO)2025-12-31$62.0Kn/a
OmniAb, Inc. (OABI)2025-12-31$565.0K-69.9%
MaxCyte, Inc. (MXCT)2025-12-31$1.77M+7.1%
bioAffinity Technologies, Inc. (BIAF)2025-12-31$60.6K-23.4%
Absci Corp (ABSI)2025-12-31$1.11M+174.0%
NRC Health (NRC)2025-12-31$10.71M-30.7%
iSpecimen Inc. (ISPC)2025-12-31$454-98.6%
OneMedNet Corp (ONMD)2025-12-31$13.0K-74.5%
Medpace Holdings, Inc. (MEDP)2025-12-31$31.36M-14.2%

Compare FOXO, OABI, MXCT, BIAF side by side · Screen every company in Services-Commercial Physical & Biological Research ↗